B of A Securities Maintains Neutral on Novavax, Raises Price Target to $18
Novavax Analyst Ratings
Novavax Analyst Ratings
Novavax (NVAX) Was Upgraded to a Hold Rating at J.P. Morgan
Novavax Analyst Ratings
Novavax Analyst Ratings
Novavax Analyst Ratings
B of A Securities Upgrades Novavax to Neutral, Raises Price Target to $12
Buy Rating for Novavax Amid Strategic Sanofi Partnership and Solid Financial Prospects
Novavax Analyst Ratings
Maintaining Hold on Novavax: Assessing Current Performance and Future Market Penetration Strategies
Optimizing for Growth: Novavax's Settlement, Cost Reductions, and CIC Vaccine Propel Buy Rating
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Align Tech (ALGN) and Novavax (NVAX)
B. Riley Lowers Novavax's Price Target to $12 From $15 After Near-Term COVID-19 Sales Estimate Revisions, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Novavax (NVAX) and Verrica Pharmaceuticals (VRCA)
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Rani Therapeutics Holdings (RANI) and Novavax (NVAX)
Analysts Conflicted on These Healthcare Names: Teva Pharmaceutical (TEVA), Novavax (NVAX) and Sanofi (OtherSNYNF)
Novavax's Matrix-M COVID-19 Vaccine Receives Buy Rating Following FDA's Emergency Use Authorization Amendment and Anticipated Demand Surge
B.Riley Financial Reaffirms Their Buy Rating on Novavax (NVAX)
B.Riley Financial Keeps Their Buy Rating on Novavax (NVAX)